Stephen K. M.D. Klasko Sells 200 Shares of Teleflex Incorporated (NYSE:TFX) Stock

Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $332.17, for a total value of $66,434.00. Following the completion of the transaction, the director now owns 936 shares of the company’s stock, valued at $310,911.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Teleflex stock traded up $6.49 on Thursday, hitting $340.48. The stock had a trading volume of 169,111 shares, compared to its average volume of 354,605. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.41 and a current ratio of 2.27. Teleflex Incorporated has a one year low of $226.02 and a one year high of $340.93. The firm has a market cap of $15.41 billion, a PE ratio of 34.39, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The firm has a 50-day moving average of $321.20.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.17 by $0.07. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The firm had revenue of $613.60 million during the quarter, compared to analyst estimates of $608.27 million. During the same quarter in the previous year, the firm earned $2.15 EPS. Teleflex’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities analysts anticipate that Teleflex Incorporated will post 11.05 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TFX. NEXT Financial Group Inc lifted its position in shares of Teleflex by 13.7% during the 2nd quarter. NEXT Financial Group Inc now owns 274 shares of the medical technology company’s stock valued at $91,000 after buying an additional 33 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Teleflex by 8.8% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 421 shares of the medical technology company’s stock valued at $127,000 after buying an additional 34 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teleflex by 17.7% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 239 shares of the medical technology company’s stock valued at $62,000 after buying an additional 36 shares in the last quarter. ETF Managers Group LLC lifted its position in shares of Teleflex by 10.2% during the 1st quarter. ETF Managers Group LLC now owns 562 shares of the medical technology company’s stock valued at $170,000 after buying an additional 52 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Teleflex by 82.8% during the 1st quarter. Quadrant Capital Group LLC now owns 117 shares of the medical technology company’s stock valued at $33,000 after buying an additional 53 shares in the last quarter. Institutional investors own 91.48% of the company’s stock.

TFX has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Raymond James restated a “market perform” rating and set a C$43.00 price target on shares of Snc-Lavalin Group in a research note on Wednesday, March 27th. Morgan Stanley reduced their target price on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday. UBS Group reiterated a “hold” rating on shares of Bayerische Motoren Werke in a research note on Friday, March 22nd. Finally, Wells Fargo & Co lowered shares of Dave & Buster’s Entertainment from an “outperform” rating to a “market perform” rating and set a $48.00 price target for the company. in a research report on Tuesday, June 11th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $333.75.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Story: Preferred Stock

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.